



Working to improve your health

7 April 2021

AFT secures new partners in Poland and Greece

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces an extension to its *Maxigesic*[®] commercialisation agreements, adding the Polish Company Mercapharm Sp.z.o.o ('Mercapharm') and the Greek Company Vianex S.A. ("Vianex") as partners for the patented combination pain killer.

These agreements cover territories with a total population of more than 48.5 million people¹.

Vianex has licensed the rights to the *Maxigesic IV*[®] intravenous product in the Greek market while Mercapharm's new distribution agreement covers the tablet, oral liquid, hot drink, fast-dissolve and dry powder sachets as well as *Maxigesic IV*.

With the addition of Poland to the oral *Maxigesic* line AFT has now secured partners in 23 out of the 27 EU member states, while *Maxigesic IV* now has partners for 22 member states.

AFT Pharmaceutical's Managing Director Dr Hartley Atkinson says: "Mercapharm has an excellent understanding of the Polish market and with a population of 37.9 million (2019) we believe the country offers great potential for *Maxigesic*."

Dr Atkinson said the new partner in Greece was well placed to drive the adoption of *Maxigesic*.

"Vianex is a strong local partner with excellent knowledge of the Greek hospital pharmaceutical sector and their strong sales reflect this," Dr Atkinson said.

Mercapharm CEO, Rafal Barski, commented "Mercapharm is excited about taking on the opportunity to distribute the *Maxigesic* pipeline in Poland. It is a novel painkiller that offers an effective alternative to traditional ibuprofen and paracetamol (acetaminophen) painkillers alone."

Maxigesic IV is expected to receive regulatory approval in Poland and Greece in mid-2022 with sales expected to begin shortly thereafter.

Maxigesic IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an intravenous formulation developed as a line extension to *Maxigesic* tablets, for use post-operatively in hospitals when patients cannot take a medicine orally.

A major Phase 3 clinical trial conducted in the USA found that *Maxigesic IV* provided significantly better pain relief than either paracetamol (acetaminophen) IV or ibuprofen IV alone in the same doses.²

Following on from the registration of Maxigesic IV in Australia and New Zealand in mid-2019, AFT has now licensed the medication in more than 90 countries. Meanwhile, the tablet form of Maxigesic has been licensed in more than 125 countries.

For and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors

Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media

Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However, the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development programme forms the basis of its international sales strategy. For more information about the company, visit our website www.aftpharm.com.

About Mercapharm Sp. z.o.o

Mercapharm Sp. z.o.o., a company incorporated in Poland, founded in 2010 and having its registered office at ul. Swietopelka 39, 81-524 Gdynia, Poland.

References

¹ Worldbank Population data 2019

²Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019). Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose combination after bunionectomy: A randomized, double-blind, factorial, placebo-controlled trial. *Clinical Therapeutics* 41 (10): 1982-1995. Research sponsored by AFT Pharmaceuticals.